Related references
Note: Only part of the references are listed.Effect of ranitidine on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
David S. Small et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans
Nagy A. Farid et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel
David S. Small et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease
C. Steven Ernest et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2008)
Patients With Poor Responsiveness to Thienopyridine Treatment or With Diabetes Have Lower Levels of Circulating Active Metabolite, but Their Platelets Respond Normally to Active Metabolite Added Ex Vivo
David Erlinge et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects
Christopher D. Payne et al.
PLATELETS (2008)
Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects
Nagy A. Farid et al.
PHARMACOTHERAPY (2008)
Prasugrel achieves greater and faster P2Y(12) receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
Lars Wallentin et al.
EUROPEAN HEART JOURNAL (2008)
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention - The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial
Stephen D. Wiviott et al.
CIRCULATION (2007)
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel
Christopher D. Payne et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2007)
Clopidogrel non responsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis
Jaapjan D. Snoep et al.
AMERICAN HEART JOURNAL (2007)
Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis
Piergiovanni Buonamici et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently
N. A. Farid et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Dose-dependent inhibition of human platelet aggregation by prasugrel and its interaction with aspirin in healthy subjects
Joseph A. Jakubowski et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2007)
Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease - Results of the Optimizing antiPlatelet Therapy In diabetes MellitUS (OPTIMUS) study
Dominick J. Angiolillo et al.
CIRCULATION (2007)
Increased risk in patients with high platelet amregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention - Is the current antiplatelet therapy adequate?
Kevin P. Bliden et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2007)
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation
John T. Brandt et al.
AMERICAN HEART JOURNAL (2007)
Clopidogrel poor responders: An objective definition based on Bayesian classification
Govinda J. Weerakkody et al.
PLATELETS (2007)
Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement
Willibald Hochholzer et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation
Tobias Geisler et al.
EUROPEAN HEART JOURNAL (2006)
A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes - The ALBION (assessment of the best loading dose of clopidogrel to blunt platelet activation, inflammation and ongoing necrosis) trial
Gilles Montalescot et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2006)
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease
T Jernberg et al.
EUROPEAN HEART JOURNAL (2006)
Biology and pharmacology of the platelet P2Y(12) receptor
Robert F. Storey
CURRENT PHARMACEUTICAL DESIGN (2006)
Platelet reactivity in patients and recurrent events post-stenting - Results of the PREPARE POST-STENTlNG study
PA Gurbel et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Matching the evaluation of the clinical efficacy of clopidogrel to platelet function tests relevant to the biological properties of the drug
B Labarthe et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention
W Hochholzer et al.
CIRCULATION (2005)